Genelux Corporation

NasdaqCM:GNLX Stock Report

Market Cap: US$111.6m

Genelux Future Growth

Future criteria checks 5/6

Genelux is forecast to grow earnings and revenue by 67.1% and 67.6% per annum respectively while EPS is expected to grow by 65.6% per annum.

Key information

67.1%

Earnings growth rate

65.60%

EPS growth rate

Biotechs earnings growth29.0%
Revenue growth rate67.6%
Future return on equityn/a
Analyst coverage

Low

Last updated28 Aug 2026

Recent future growth updates

Recent updates

Analysis Article • Feb 13

Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 31

Genelux: H2 2025 PRROC Data Is A Major Inflection Point

Summary Topline results from the phase 3 OnPrime/GOG-3076 study using Olvi-Vec for the treatment of patients with platinum-resistant recurrent ovarian cancer are expected in the second half of 2025. Interim data from the phase 2 U.S. trial using Olvi-Vec for the treatment of patients with non-small cell lung cancer is expected in mid-2025. Interim results from the phase 1b/2 China study, using Olvi-Vec for the treatment of patients with small-cell lung cancer, are expected second half of 2024. The global ovarian cancer treatment drugs market size is expected to reach $5.45 billion by 2033; About 85% of patients with ovarian cancer will experience recurrence at some point. Read the full article on Seeking Alpha
Analysis Article • Aug 24

We're Keeping An Eye On Genelux's (NASDAQ:GNLX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jan 29

We're Hopeful That Genelux (NASDAQ:GNLX) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 27

We're Not Very Worried About Genelux's (NASDAQ:GNLX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Earnings and Revenue Growth Forecasts

NasdaqCM:GNLX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202866-5N/AN/A4
12/31/20278-39N/A-405
12/31/2026N/A-36N/A-265
6/30/20260-36-29-25N/A
3/31/20260-34-28-26N/A
12/31/20250-32-26-25N/A
9/30/2025N/A-32-24-23N/A
6/30/2025N/A-30-23-23N/A
3/31/2025N/A-30-23-22N/A
12/31/20240-30-22-21N/A
9/30/20240-28-24-24N/A
6/30/20240-27-22-21N/A
3/31/20240-26-21-20N/A
12/31/20230-28-21-20N/A
9/30/20230-25-16-15N/A
6/30/202311-15-15-14N/A
3/31/202311-12-11-11N/A
12/31/202211-5-4-4N/A
9/30/202211-5-1-1N/A
6/30/2022N/A-13-1-1N/A
3/31/2022N/A-17-1-1N/A
12/31/2021N/A-16-7-7N/A
3/31/2021N/A-13-8-8N/A
12/31/2020N/A-14-7-7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GNLX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.7%).

Earnings vs Market: GNLX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: GNLX is expected to become profitable in the next 3 years.

Revenue vs Market: GNLX's revenue (67.6% per year) is forecast to grow faster than the US market (13.4% per year).

High Growth Revenue: GNLX's revenue (67.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if GNLX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 02:16
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genelux Corporation is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian Kemp DolliverBrookline Capital Markets
Emily BodnarH.C. Wainwright & Co.
null nullH.C. Wainwright & Co.